CancerVax Announces Positive Clinical Results for CANVAXIN Vaccine as Treatment for Stage III Melanoma.Business Editors & Health/Medical Writers BIOWIRE2K LILLE, France--(BW HealthWire)--April 22, 2002 CancerVax(R) Corporation announced today that results of a study presented at the 11th Annual Congress of the European Society of Surgical Oncology surgical oncology Oncological surgery The field of surgery dedicated to the operative ablation of neoplasia, generally, 'solid' tumors in Lille, France, indicated that CANVAXIN(TM), the Company's therapeutic cancer vaccine The term cancer vaccine is often used to describe a process whereby a person's immune system is coaxed into recognizing and destroying malignant cells without harming normal cells. , increased median overall survival in the post-surgical treatment of patients with Stage III melanoma. The results are from a retrospective, matched pair analysis of 635 pairs of patients from a Phase 2 clinical study undertaken at the John Wayne Cancer Institute in Santa Monica, California For other uses, see Santa Monica (disambiguation). Santa Monica is a coastal city in western Los Angeles County, California, USA. Situated on Santa Monica Bay of the Pacific Ocean, it is surrounded by the City of Los Angeles — Pacific Palisades and Brentwood on the north, . In this study, patients who received the CANVAXIN(TM) vaccine were matched with patients who did not receive the vaccine, based on known prognostic factors that affect survival in patients with Stage III melanoma. In patients treated with the CANVAXIN(TM) vaccine, the median overall survival was 58 months compared to 28 months for patients not treated with the vaccine (p=0.0001). The CANVAXIN(TM) vaccine is an allogeneic allogeneic /al·lo·ge·ne·ic/ (-je-ne´ik) 1. having cell types that are antigenically distinct. 2. in transplantation biology, denoting individuals (or tissues) that are of the same species but antigenically , whole cell vaccine that expresses at least thirty known tumor-associated antigens, which the Company believes enhances overall immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. to the cancer. Unlike chemotherapy, the CANVAXIN(TM) vaccine harnesses the body's own immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to produce both a cellular (production of T cells T cells A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood. ) and humoral hu·mor·al adj. 1. Relating to body fluids, especially serum. 2. Relating to or arising from any of the bodily humors. Humoral Pertaining to or derived from a body fluid. (production of antibodies) response to the cancer. CancerVax plans to seek approval of the CANVAXIN(TM) vaccine from the U.S. Food & Drug Administration and other regulatory agencies around the world if the results of its ongoing Phase 3 studies in the treatment of advanced stage melanoma are positive. About CancerVax Corporation (www.cancervax.com) CancerVax Corporation is a privately held biotechnology company focused on the research, development and commercialization of novel therapeutic vaccines, angiogenesis inhibitors and monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). for the treatment and control of cancer. CancerVax maintains its corporate and R&D headquarters in Carlsbad, California, and its biologics manufacturing facility in Los Angeles, California. CancerVax cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by CancerVax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in CancerVax's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects Side effects Effects of a proposed project on other parts of the firm. or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. CancerVax(R) and CANVAXIN(TM) are trademarks of CancerVax(R) Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion